,12 The recent regulatory approval of CYTALUX, a folate-targeted probe for lung and ovarian cancers, and Lumicell, a cathepsin-activated probe for breast cancer, marks a milestone in utilizing tumor-targeted probes within the NIR spectrum.13 The gene discussed is CTSS; the disease is neoplasm.